Vanguard Group Inc. Has $71.67 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Vanguard Group Inc. grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 17.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,273,750 shares of the company’s stock after acquiring an additional 775,722 shares during the period. Vanguard Group Inc. owned 0.06% of Amylyx Pharmaceuticals worth $71,670,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AMLX. Millennium Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after purchasing an additional 2,487,617 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Amylyx Pharmaceuticals by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after purchasing an additional 143,065 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $149,000. Acadian Asset Management LLC increased its position in Amylyx Pharmaceuticals by 135.1% during the second quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock worth $3,645,000 after buying an additional 326,976 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in Amylyx Pharmaceuticals during the second quarter valued at about $113,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi?year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer?term upside.
• Positive Sentiment: Avexitide remains the company’s key near?term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well?funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near?term profitability remains a multi?quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short?interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near?term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Analyst Ratings Changes

A number of brokerages have weighed in on AMLX. HC Wainwright boosted their price target on Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. Bank of America increased their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Finally, Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $21.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.56.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $13.85 on Friday. The company has a market capitalization of $1.53 billion, a PE ratio of -8.94 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a one year low of $3.11 and a one year high of $17.49. The company’s fifty day moving average price is $13.94 and its 200 day moving average price is $13.22.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Joshua B. Cohen sold 136,193 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $13.59, for a total transaction of $1,850,862.87. Following the completion of the sale, the chief executive officer owned 3,378,621 shares in the company, valued at $45,915,459.39. This represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Karen Firestone bought 8,100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average price of $12.45 per share, with a total value of $100,845.00. Following the purchase, the director owned 63,100 shares in the company, valued at $785,595. This trade represents a 14.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 151,203 shares of company stock worth $2,028,385 over the last quarter. 12.30% of the stock is currently owned by company insiders.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.